Abstract: The year 2017  experiences much progress in the diagnosis and treatment of haematologic malignancies， which is mainly reflected in the further study of molecular markers and more applications in accurate diagnosis and risk stratification. More   molecular targeted drugs are used in clinical treatment， and good effects are  obtained. Immunotherapy， especially chimeric antigen receptor T cell immunotherapy produced significant effect in the treatment of refractory relapse B cell malignant tumor.

Key words: hematologic neoplasms, diagnosis, therapy, molecular targeted therapy